We are developing paradigm-shifting process improvement technologies to enable the cost-effective production of biologics and biosimilar drugs for the Indian market. Biologics sometimes referred to as large-molecule drugs, are protein-based therapeutics that are produced using unique cell lines, including mammalian cells, yeast, and bacteria. Unlike small-molecule drugs and generics that are manufactured via chemical synthesis, biologics undergo essential post-translational modifications when manufactured in living cells.

Through our biologics manufacturing technology, we plan to:

• Significantly decrease operating expenditures, overall bioprocess line downtime, and biological product loss when compared to traditional monoclonal antibody manufacturing approaches
• Increase the overall purity of monoclonal antibodies
• Replace centrifugation and depth filtration processes
• Replace all traditional column chromatography process steps (e.g., Protein A affinity column chromatography, ion exchange chromatography, hydrophobic interaction chromatography)
• Enable the utilization of smaller, more streamlined equipment (e.g., smaller bioreactor volumes and downstream bioprocess equipment)

Treatment: can be used a treatment for ischemic stroke and could extend the therapeutic time window by protecting tissue at risk of ischemia due to its high capacity to carry and efficiently deliver oxygen to tissues that lack oxygen using precision medicine.

Diagnostics: provide diagnostic metabolic and inflammatory information, which will inform the use of therapeutics in ischemic stroke, ischemic heart diseases, cancer, and other indications.

A common and prominent complication of advanced COVID-19 is acute hypoxemic respiratory insufficiency requiring oxygen and ventilation therapies. According to the World Health Organization (WHO), most patients with COVID-19 infection will be managed with home isolation and symptomatic relief, with only 20% of symptomatic patients requiring hospital admission.

Any means of improving oxygenation by only using a face mask could reduce or mitigate the need for ICU beds. This could be transformational in the management of hypoxemic COVID-19 patients, especially in the developing world. We envisage that our products, due to their capacity to carry oxygen, will be a solution to improving blood oxygenation using a face mask and thereby keeping the patient in the green zone managed in a medical bed and preventing progression into the ICU.

Vulvovaginal atrophy (VVA) is a common, underreported and severely overlooked medical condition whose urogenital symptoms (e.g. dyspareunia, vaginal dryness, vaginal irritation, increased urinary tract infections) will be experienced by most women at some point in their lives. The progression of VVA is directly correlated to declining levels of estrogen with the onset of menopause. Our platform formulation technology comprises the development of an emulsified cream that uniquely combines specific combinations of well-known, generally recognized as safe (GRAS) ingredients that manifest a range of physicochemical properties to mimic the dynamic surface of the vaginal mucosa.

The initial product will serve as the base formulation across all our pipeline products, as this base formulation is designed to easily incorporate active ingredients to create a pipeline of over-the-counter (OTC) and prescription products across a number of vaginal health-based pathologies.